Veeda Oncology

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Veeda Oncology sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 5 completed early-phase tilt top decile by trial count

Veeda Oncology: 9 sponsored US clinical trials, none currently recruiting.

Veeda Oncology sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metastatic Breast Cancer, with 1 trials.

Top-decile sponsor footprint

Veeda Oncology ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

TERMINATED Phase 2

A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer

NCT00607438
TERMINATED Phase 4

A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting

NCT00418678
TERMINATED Phase 2

PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

NCT00313482
COMPLETED Phase 2

A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC

NCT00251524
COMPLETED Phase 2

A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer

NCT00251446
COMPLETED Phase 2

A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer

NCT00251472
TERMINATED Phase 2

A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome

NCT00251511
COMPLETED Phase 2

A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

NCT00251485
COMPLETED Phase 2

Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

NCT00251498

Phase Distribution

PhaseTrial count
Phase 2 8
Phase 4 1

Therapeutic Areas

Metastatic Breast Cancer 1

How the Veeda Oncology early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 5 completed (56%).

Phase mix: 1 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Metastatic Breast Cancer (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Veeda Oncology: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Veeda Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Veeda Oncology4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Veeda Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Veeda Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Veeda Oncology page

9 registered trials is a research-attention snapshot, not an endorsement of Veeda Oncology or any single study.

  • None of Veeda Oncology's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Metastatic Breast Cancer is the condition Veeda Oncology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metastatic Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Veeda Oncology pipeline card: 9 registered trials from official public datasets.Report a data error.